Supratentorial ependymomas encompass: 1) supratentorial ependymomas with YAP1-fusion, grade 2-3 pediatric tumors with good prognosis, which maybe targeted by YAP/TAZ inhibitors such as dasatinib and pazopanib; 2) supratentorial ependymomas with ZFTA-fusion, grade 3 entities with worse prognosis and intraventricular predilection, previously classified as RELA-fusion positive; 3) supratentorial ependymomas NOS/NEC, grade 2-3 tumors with no-YAP1/ZFTA fusion, which represent a subgroup of exclusion (80). This evidence concerns the gene RELA and ependymoma.